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c) The number of ) plays a decisive role in oxidative metabolism of xenobiotics and endogenous substances. CYPs have molecular and functional diversity with thousands of isoforms in many species (http:/www.imm.ki.se/CYPalleles/). In drug development, species differences in isoform composition and substrate specificity of CYP is a great concern for extrapolation of animal data to humans (Guengerich, 1997) . For example, CYP3A4 is the major isoform expressed in human liver, whereas CYP2C is the most abundant isoform in rat liver (Cheng and Schenkman, 1982) . Moreover, it has been reported that S-mephenytoin 4'-hydroxylation is catalyzed by human CYP2C19, but not rat orthologous isoforms (CYP2C6/11/12/13) (Kobayashi et al., 2002) . Therefore, for prediction of human metabolism from animal data, it is important to determine the species differences in the CYP functions.
In the pharmaceutical industry, beagle dogs are commonly used as non-rodent animals for toxicological and pharmacological studies of drug candidates. Dog pharmacokinetic data along with in vitro metabolic data can be very useful for the prediction of human in vivo pharmacokinetics and interpretation of toxicity and efficacy results in both species. In dogs, several CYPs have been cloned and sequenced including CYP1A1/2 (Uchida et al., 1990; Fukuta et al., 1992) , CYP2B11 (Graves et al., 1990) , CYP2C21/41 (Uchida et al., 1990; Blaisdell et al. ,
1998), CYP2D15 (Sakamoto et al., 1995) , CYP2E1 (Lankford et al., 2000) and CYP3A12/26 (Ciaccio et al., 1991; Fraser et al., 1997) . For almost all of these CYPs, heterologous expression, functional characterization and comparison of substrate specificity with corresponding human
CYPs have been investigated. However, functional characterization of dog CYP1A2 has not been reported. CYP1A2 is constitutively expressed in human and animal liver, and is responsible for the metabolism of many drugs including caffeine, phenacetin and theophylline in humans (Rendic and Di Carlo, 1997) . In addition, it plays a major role in the metabolic activation of carcinogens such as polycyclic aromatic hydrocarbons and aromatic amines (Guengerich, 1997; Rendic and Di Carlo, 1997) . For reliable and effective preclinical studies using dogs, it is necessary to characterize the species differences in CYP1A2 function between dogs and humans.
deficient and wild-type dog liver microsomes, the contribution of CYP1A2 to the metabolism can be determined.
In this study, to determine substrate specificity of dog CYP1A2 and to compare the substrate specificity between dogs and humans, in vitro metabolism studies using the following 11 CYP substrates in CYP1A2-deficient dog, wild-type dog and human liver microsomes were conducted:
phenacetin, ethoxyresorufin, tacrine and caffeine for exogenous human CYP1A2 substrates; melatonin, 9-cis-retinal and estradiol for endogenous human CYP1A2 substrates; aminopyrine, aniline, bufuralol and midazolam for other CYPs substrates (Rendic and Di Carlo, 1997; Yamazaki et al., 1998; Zhang et al., 2000; Facciola et al., 2001) .
MATERIALS and METHODS

Chemicals.
Aminopyrine, aniline, antipyrine, caffeine, 6-chloromelatonin, chlorzoxazone, 9-cis-retinal, 9-cis-retinoic acid, dextrorphan, enprofylline, estradiol, ethoxyresorufin, 2-hydroxyestradiol, 6-hydroxymelatonin, 1-hydroxytacrine maleate, melatonin, paraxanthine, tacrine hydrochloride, theobromine, theophylline and 1,3,7-trimethyluric acid were purchased from Sigma Chemical Co.
(St. Louis, MO). p-Aminophenol, midazolam and phenacetin were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). α-Naphthoflavone (ANF) was purchased from Nacalai Tesque (Kyoto, Japan). Bufuralol hydrochloride, 1'-hydroxybufuralol and 1'-hydroxymidazolam were purchased from Toronto Research Chemicals Inc. (Ontario, Canada). All other reagents were of the highest grade commercially available.
Genotyping.
Beagle dogs were obtained from Covance Research Products Inc. (Kalamazoo, MI). A polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) was used to detect the C1117T mutation (Mise et al., 2004a) . Genomic DNA was extracted from dog whole blood using a DNAeasy tissue kit (Qiagen, Hilden, Germany). Forward and reverse primers were content was determined by the method of Lowry et al. (1951) using bovine serum albumin as a standard. Total CYP content was determined by the method of Omura and Sato (1964) .
Human liver microsomes (mixed gender, pool of 50 individuals) were purchased from XenoTech LLC (Lenexa, KS).
Aniline hydroxylase (AN) assay
Aniline (5 mM) was incubated for 30 min at 37°C in 1 ml of a reaction mixture consisting of 50 mM phosphate buffer (pH 7.4), 1 mg/ml dog or human liver microsomes and 0.8 mM NADPH.
p-Aminophenol, hydroxylated metabolite, was measured according to the method of Imai et al. 
Tacrine 1-hydroxylase (TC) assay
Tacrine (25 µM) was incubated for 15 min at 37°C in 500 µl of reaction mixture consisting of 50 mM phosphate buffer (pH 7.4), 0.8 mg/ml dog or human liver microsomes and 0.8 mM NADPH.
The reaction was started by adding NADPH and stopped by adding 1.5 ml of acetonitrile, with 25
µl of 50 µM antipyrine as an internal standard. After centrifugation at 900g for 10 min, the supernatant was evaporated to dryness, and then the residue was dissolved in the mobile phase for
high-performance liquid chromatography (HPLC) analysis. 1-Hydroxytacrine was quantified by HPLC (1100 liquid chromatography) using a reverse-phase column (Inertsil ODS-3, 3.0x100 mm)
at 40°C with a flow rate of 0.4 ml/min. Mobile phase consisted of solvent A (0.05% trifluoroacetic acid) and solvent B (acetonitrile). The gradient used was as follows: 13% solvent B (0-5 min); 13-25% (5-10 min); 25-80% (10-10.5 min); 13% (11-15 min). Wavelength of the detector was 250 nm. Intra-and inter-assay CVs for 0.5 µM 1-hydroxytacrine were 0.9% and 3.1%, respectively.
Caffeine 7-demethylase (13X), 3-demethylase (17X), 1-demethylase (37X) and 8-hydroxylase (137U) assay
Caffeine (1 mM) was incubated for 30 min at 37°C in 500 µl of a reaction mixture consisting of 50 mM phosphate buffer (pH 7.4), 1 mg/ml dog or human liver microsomes and 0.8 mM NADPH. The reaction was started by adding NADPH and stopped by adding 1.5 ml of acetonitrile, with 50 µl of 20 µM enprofylline as an internal standard. After centrifugation at 900g for 10 min, the supernatant was evaporated to dryness, and then the residue was dissolved in the mobile phase for HPLC analysis. Theophylline (7-demethylated metabolite), paraxanthine (3-demethylated metabolite), theobromine (1-demethylated metabolite) and trimethyluric acid (8-hydroxylated metabolite) were quantified using HPLC under the same conditions as the TC
assay. Mobile phase consisted of solvent A (0.05% trifluoroacetic acid) and solvent B (acetonitrile). The gradient used was as follows: 7% solvent B (0-6 min); 7-20% (6-10 min); 20-80% (10-10.5 min); 80-7% (10.5-11 min); 7% (11-15 min). Wavelength of the detector was 280 nm. Intra-and inter-assay CVs were 1.7% and 3.8% for 0.5 µM theophylline, 1.9% and 4.1%
for 0.5 µM paraxanthine, 1.7% and 6.4% for 0.5 µM theobromine and 1.7% and 1.4% for 0.5 µM trimethyluric acid, respectively.
Melatonin 6-hydroxylase (MLT) assay.
Melatonin 6-hydroxylase assay was performed as described previously with several modifications (Ma et al., 2005) . Melatonin (25 µM) was incubated for 15 min at 37°C in 100 µl of reaction mixture consisting of 50 mM phosphate buffer (pH 7.4), 0.5 mg/ml dog or human liver microsomes and 0.8 mM NADPH. For human liver microsomes, inhibitory effects of 1 µM ANF, human CYP1A2 inhibitor, were also evaluated. The reaction was started by adding NADPH and stopped by adding 100 µl of acetonitrile, with 50 µl of 2 µM 6-chloromelatonin as an internal standard. After centrifugation at 900g for 10 min, 6-hydroxymelatonin was quantified by 6-chloromelatonin. Intra-and inter-assay CVs for 0.5 µM 6-hydroxymelatonin were 3.2% and 3.8%, respectively.
9-cis-Retinal oxidase (RAL) assay.
9-cis-Retinal oxidase assay was performed as described previously with several modifications (Zhang et al., 1998) . 9-cis-Retinal (100 µM) was incubated for 20 min at 37°C in 500 µl of reaction mixture consisting of 50 mM phosphate buffer (pH 7.4), 1 mg/ml dog or human liver microsomes and 0.8 mM NADPH. For human liver microsomes, inhibitory effects of 1 µM ANF were also evaluated. The reaction was stopped by adding 2 ml of ethyl acetate containing 0.005% butylated hydroxytoluene. Metabolites were extracted three times with ethyl acetate. Extracts were pooled, dried under a nitrogen stream, and then dissolved in methanol. 9-cis-Retinoic acid was quantified using HPLC under the same conditions as the TC assay. and inter-assay CVs for 0.5 µM 9-cis-Retinoic acid were 2.6% and 8.5%, respectively.
Estradiol 2-hydroxylase (E2) assay.
Estradiol (20 µM) was incubated for 20 min at 37°C in 500 µl of reaction mixture consisting of 50 mM phosphate buffer (pH 7.4), 0.8 mg/ml dog or human liver microsomes and 0.8 mM NADPH. For human liver microsomes, inhibitory effects of 1 µM ANF were also evaluated.
The reaction was stopped by adding 2 ml of ethyl acetate, with 50 µl of 20 µM chlorzoxazone as an internal standard. After centrifugation at 900g for 10 min, the extract was evaporated to dryness, and then the residue was dissolved in methanol. nm. Intra-and inter-assay CVs for 0.5 µM 2-hydroxyestradiol were 2.4% and 4.7%, respectively.
Other assays.
Ethoxyresorufin O-deethylase (EROD), phenacetin O-deethylase (POD) and aminopyrine N-demethylase (AP) assays were performed as described previously (Mise et al., 2004b) .
Statistical analysis.
Statistical significance was tested using Dunnett's multiple comparison procedure (significance levels: 5%, two-tailed test) between C/C and C/T, T/T genotyped dogs.
RESULTS
Metabolism of substrates for human CYPs except CYP1A2.
Activities of AP, AN, BF and MDZ, that are not catalyzed by human CYP1A2, in genotyped dog and human liver microsomes are shown in Table 1 . There was no statistical difference in these activities between C/C, C/T and T/T dogs. These results indicate that neither human CYP1A2 nor dog CYP1A2 catalyze these reactions.
In quantitative comparisons with humans, activities of AP and BF in dogs were comparable to those in humans, however, activities of AN and MDZ in dogs were lower than those in humans.
Metabolism of exogenous substrates for human CYP1A2.
Activities of POD, EROD and TC in genotyped dog and human liver microsomes are shown in Figure 2 . These activities were significantly lower in T/T dogs than in C/C dogs. In addition, EROD activity was significantly lower in C/T dogs than in C/C dogs. These significant differences between genotypes were also observed in activities per nmol P450, indicating that the difference is not caused by difference in total CYP content. POD and TC activities in C/T dogs tended to be lower than those in C/C dogs, but this finding is not statistically significant. These results indicate that dog CYP1A2 is responsible for these activities.
In quantitative comparisons with humans, activities of POD and TC in C/C and C/T dogs were equivalent to activities in humans. However, these activities in T/T dogs were much lower than those in humans (28% and 29%, respectively). These results suggest that T/T dog is not a good model for quantitative extrapolation of CYP1A2 metabolism to human.
Activities of caffeine 13X, 17X, 37X and 137U in genotyped dog and human liver microsomes are shown in Table 2 . There was no difference in caffeine metabolism between C/C, C/T and T/T dogs, indicating that, unlike human, dog CYP1A2 is not involved in these reactions. In comparisons with humans, although 17X pathway was the main metabolic pathway both in humans and dogs, the contribution of 13X and 137U to caffeine metabolism in dogs were 15.4 and 18.4%, respectively, higher than those in humans (4.7 and 3.9%, respectively). These results suggest that the metabolic profile of caffeine in dogs is different from that in humans.
Metabolism of endogenous substrates for human CYP1A2.
Activities of MLT, RAL and E2 in genotyped dog and human liver microsomes are shown in MLT activity in T/T dogs was 30% lower than that in C/C dogs (P<0.05). These results indicate that dog CYP1A2 is only partially involved in MLT activity. In human liver microsomes, MLT activity was strongly inhibited by CYP1A2 inhibitor, ANF (94% inhibition), indicating that
CYP1A2 is responsible for MLT activity.
RAL and E2 activity in human liver microsomes were strongly and partially inhibited by ANF (83% and 44% inhibition, respectively). However, RAL and E2 activities were equivalent between T/T, T/C and C/C dogs. These results indicate that dog CYP1A2, unlike human CYP1A2, is not involved in RAL and E2 activity.
In quantitative comparisons with humans, RAL and E2 activities in dogs were lower than those in humans.
DISCUSSION
In this study, substrate specificity of dog CYP1A2 was investigated using CYP1A2-deficient and wild-type dog liver microsomes, and compared to human CYP1A2.
Results indicated that dog CYP1A2 has POD, EROD and TC activities, similarly to human CYP1A2 (Figure 2 ). Although POD in dog liver microsomes is considered to be dog CYP1A2 (Chauret et al., 1997) , direct evidence, such as immunoinhibition studies, has not been reported.
The current study produced direct evidence that dog CYP1A2 is largely responsible for POD activity in dog liver microsomes. Moreover, as the major metabolite of dog urine after administration of phenacetin is acetaminophen, an O-deethylated metabolite (Podder et al., 1988) , dog CYP1A2 is the major CYP isoform involved in phenacetin metabolism in dogs. EROD activity is used as an in vitro CYP1A1/2 marker activity not only in humans but also in dogs (Graham et al., 2002) . Although heterologously expressed dog CYP1A1 and CYP1A2 catalyzed EROD activity, the contribution of CYP1A2 in EROD activity in dog liver microsomes has been unknown (Gibson et al., 2005) . Our results suggested that CYP1A2 is largely responsible for EROD activity in dog liver microsomes. TC in human is CYP1A2 (Madden et al., 1993) , however the CYP isoform responsible for TC activity in dogs has been unknown. In this study, CYP1A2 was demonstrated to be responsible for TC activity in dog liver microsomes. In contrast, dog CYP1A2 was not involved in AP, AN, BF and MZ activities (Table 1) . AP and AN are used as marker activities for CYP2B/3A and CYP2E1, respectively, in dogs (Tanaka et al., 1998; Nakata et al., 2000) . In addition, it has been reported that dog CYP2D15 and CYP3A12
have BF and MZ activity, respectively (Roussel et al., 1998; Carr et al., 2006) . Our results are consistent with these previous findings.
17X activity, the major metabolic pathway of caffeine, is commonly used as a CYP1A2 marker activity in both humans and dogs (Tanaka et al., 1998) . Moreover, 17X activity is catalyzed by isoforms induced by β-naphthoflavone in dogs (Aldridge and Neims, 1979) , however it has not been determined whether CYP1A2 is involved in 17X activity in the uninduced state. In the current study, there was no difference in caffeine metabolism between C/C, C/T and T/T dogs indicating that dog CYP1A2 is not involved in 17X activity at a substrate concentration of 1 mM This article has not been copyedited and formatted. The final version may differ from this version. (Table 3) . Generally, in the in vitro caffeine metabolism study, the substrate concentration is at least 1 mM (Tanaka et al., 1998) . Therefore, it should be recognized that 17X activity is not a marker activity for CYP1A2 in dog liver microsomes at a substrate concentration of 1 mM. The metabolic profile in dog liver microsomes was also different from human liver microsomes, with the contribution of 13X to caffeine metabolism higher in dogs than humans (Table 3) . These results are supported by previous reports describing that 3-and/or 7-demethylation as the primary routes of caffeine metabolism in dogs (Aldridge and Neims, 1979) .
Some endogenous substances are substrates for human CYP1A2 (e.g. melatonin, retinoids, estrogens and uroporphyrinogen). The pineal hormone melatonin is metabolized to 6-hydroxymelatonin mainly by human CYP1A2 and clearance of orally administered melatonin is significantly correlated with the caffeine clearance, a marker activity for human CYP1A2 (Facciola et al., 2001; Hartter et al., 2001 ). 9-cis-Retinal is oxidized by human CYP1A2 to 9-cis-retinoic acid, a ligand for retinoic acid receptor and retinoid X receptor (Duester, 1996; Zhang et al., 2000) .
Estradiol, a main estrogen, is metabolized to 2-hydroxyestradiol by human CYP1A2 and CYP3A4 (Yamazaki et al., 1998) . Agreeing with previous studies, our study demonstrats that CYP1A2 inhibitor inhibited MLT, RAL and E2 by 94%, 83% and 44%, respectively, in human liver microsomes (Fig.3) . In contrast, dog CYP1A2 was found to not be responsible for MLT, RAL and E2 activities. These species differences in CYP1A2 substrate specificity for endogenous
substances permit us to speculate that the contribution of CYP1A2 in physiological homeostasis is different between humans and dogs. In fact, a CYP1A2-deficient phenotype in humans has not yet been reported (http:/www.imm.ki.se/CYPalleles/), although CYP1A2-deficient dogs exist (Mise et al., 2004a; Tenmizu et al., 2004) . However, the contribution of CYP1A2 to the metabolism of endogenous substances in vivo is not completely understood. For example, it has been reported that extrahepatic CYP1B1 has MLT activity (Ma et al., 2005) and that cytosolic aldehyde dehydrogenase and intestinal microsomal CYP2J4 has RAL activity (Duester, 1996; Zhang et al., 1998) . To characterize the physiological role of CYP1A2, additional studies are required.
In generally, pharmacokinetic data from animals along with in vitro metabolic data are used for the prediction of human in vivo pharmacokinetics. Also, in toxicological or pharmacological studies, the correlation between the systemic exposure of a compound and its toxicological or pharmacological effect is evaluated for the prediction of effects in humans. In these preclinical studies, the genetic homogeneity of the animals used will be very important for reliable prediction.
The current study demonstrates that POD, EROD and TC activities in beagle dogs are significantly different between CYP1A2 genotypes (C/C, C/T and T/T). The genotype frequency of T/T, CYP1A2-deficient dog, is more than 10% (Mise et al., 2004a; Tenmizu et al., 2004) . Therefore, CYP1A2 genotypes in beagle dogs should be a great concern for obtaining reliable preclinical
study data (Kamimura, 2006) .
In this study, 11 CYP activities were quantitatively compared between dogs and humans. AN, MDZ, RAL and E2 activities were lower in dogs than humans. This data is basic to understanding species differences in CYP function and useful for animal selection in preclinical studies.
CYP1A2 which activates polycyclic aromatic hydrocarbons and aromatic amines is key enzyme in chemical carcinogenesis in humans and rats (Guengerich, 1997) . However, in dogs, the contribution of CYP1A2 in the carcinogen metabolism is unknown. Using our approach applied to the current study, it may be possible to determine the contribution of CYP1A2 to the carcinogens metabolism in dogs, and to discus its toxicological significance.
In conclusion, substrate specificity of CYP1A2 in beagle dogs and a species difference in the specificity between beagle dogs and humans were determined. Tacrine, ethoxyresorufin and phenacetin are probe substrates for CYP1A2 in both dogs and humans. However, caffeine, melatonin, 9-cis-retinal and estradiol, which are substrate for human CYP1A2, are not good substrates for dog CYP1A2. The finding that there are species differences in substrate specificity of CYP1A2 between humans and beagle dogs is an important issue and must be considered for preclinical studies using beagle dogs.
deduced amino acid sequences of a dog liver cytochrome P-450 of the IIIA gene subfamily. 
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